Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

Chong Kun Dang Signs KIO-301 Deal

Chong Kun Dang has joined hands with a US pharmaceutical company to treat a rare inherited retinal disease estimated to affect more than 10,000 patients in South Korea.Chong Kun Dang signed a licensing agreement on August 21 with Kiora Pharmaceuticals, a US pharmaceutical company specializing in oph

  • Chong Kun Dang partners with Kiora Pharmaceuticals for KIO-301 development.
  • KIO-301 targets retinitis pigmentosa, affecting over 10,000 South Koreans.
  • Collaboration aims to expedite domestic clinical and approval processes.

More from Friday 21 August →